Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups
In Vivo's latest rankings of the top 100 revenue earners in the medical technology industry show the groups leading the global market tightening their grip further in 2017. This was partly a function of providers choosing to partner more and more with fewer suppliers who can offer a wider provision of services. But it was steady as she goes for most of the multinational medtechs, with some major exceptions, and there will be more M&A reflected in next year's rankings, based on 2018 revenues.
You may also be interested in...
Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.
Earlier detection of cancer can only happen with a concerted, government led effort, more investment and cross industry collaboration, says CRUK. Its Roadmap to the Future sets out the milestones for achieving that aim.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.